New studies highlight CAR-T therapy’s success in treating acute lymphoblastic leukemia and lymphoma.
20 years ago, virtually all cancer treatments involved surgery, chemotherapy, and radiation. But the past two decades have seen advances in targeted therapies like trastuzumab (HerceptinĀ®) and imatinib (GleevecĀ®), which target cancer cells by homing in on molecular changes in these cells. Today, targeted therapies like these are now standard treatments for various cancers.
One of the most recent types of therapy is immunotherapy, which strengthens a patient’s immune system so they can better attack tumors. The cancer community now widely considers immunotherapy the “fifth pillar” of cancer treatment. Among the various immunotherapies available today, adoptive cell transfer (ACT) is one of the latest approaches. ACT collects and uses patients’ immune cells to treat their cancer. There are various types of ACT, but the type that has progressed furthest in clinical development is CAR-T therapy. Researchers are gaining …